Eli Lilly and Company (NYSE:LLY) Shares Acquired by Moloney Securities Asset Management LLC


Share on StockTwits

Moloney Securities Asset Management LLC raised its position in Eli Lilly and Company (NYSE:LLY) by 2.3% during the first quarter, HoldingsChannel.com reports. The firm owned 4,235 shares of the company’s stock after buying an additional 96 shares during the quarter. Moloney Securities Asset Management LLC’s holdings in Eli Lilly and were worth $791,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in LLY. Price T Rowe Associates Inc. MD lifted its holdings in Eli Lilly and by 51.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 12,094,613 shares of the company’s stock worth $2,042,017,000 after acquiring an additional 4,082,728 shares during the last quarter. Norges Bank purchased a new position in shares of Eli Lilly and in the fourth quarter worth approximately $1,463,293,000. Janus Henderson Group PLC boosted its stake in Eli Lilly and by 5.2% in the 4th quarter. Janus Henderson Group PLC now owns 6,124,921 shares of the company’s stock worth $1,034,108,000 after purchasing an additional 302,296 shares during the period. Fisher Asset Management LLC lifted its holdings in shares of Eli Lilly and by 9.3% in the first quarter. Fisher Asset Management LLC now owns 5,508,308 shares of the company’s stock valued at $1,029,062,000 after purchasing an additional 470,518 shares in the last quarter. Finally, California Public Employees Retirement System increased its holdings in shares of Eli Lilly and by 2.5% in the 4th quarter. California Public Employees Retirement System now owns 4,575,362 shares of the company’s stock valued at $772,504,000 after purchasing an additional 110,280 shares during the period. Hedge funds and other institutional investors own 75.59% of the company’s stock.

Shares of LLY stock opened at $185.92 on Tuesday. Eli Lilly and Company has a 12-month low of $129.21 and a 12-month high of $218.00. The firm has a fifty day moving average of $185.84 and a 200-day moving average of $176.06. The firm has a market capitalization of $178.30 billion, a price-to-earnings ratio of 30.38, a price-to-earnings-growth ratio of 1.57 and a beta of 0.37. The company has a quick ratio of 1.06, a current ratio of 1.36 and a debt-to-equity ratio of 3.27.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Monday, April 26th. The company reported $1.87 earnings per share for the quarter, missing analysts’ consensus estimates of $2.12 by ($0.25). Eli Lilly and had a return on equity of 166.45% and a net margin of 24.01%. The firm had revenue of $6.81 billion for the quarter, compared to analyst estimates of $7.10 billion. During the same period last year, the company earned $1.75 EPS. The company’s revenue was up 16.1% compared to the same quarter last year. Research analysts expect that Eli Lilly and Company will post 7.56 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 10th. Stockholders of record on Friday, May 14th will be paid a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 1.83%. Eli Lilly and’s dividend payout ratio is presently 56.29%.

LLY has been the topic of a number of research analyst reports. Mizuho lowered their target price on Eli Lilly and from $228.00 to $216.00 and set a “buy” rating on the stock in a report on Wednesday, April 28th. Barclays cut their price objective on shares of Eli Lilly and from $232.00 to $227.00 and set an “overweight” rating for the company in a research report on Wednesday, April 28th. Truist lifted their target price on Eli Lilly and from $200.00 to $215.00 in a research report on Monday, February 1st. Truist Securities upped their price target on Eli Lilly and from $215.00 to $225.00 and gave the company a “buy” rating in a report on Monday, March 22nd. Finally, Cowen lifted their price objective on Eli Lilly and from $195.00 to $235.00 and gave the stock an “outperform” rating in a report on Friday, February 12th. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $200.75.

In related news, Director Jackson P. Tai acquired 1,366 shares of the company’s stock in a transaction dated Friday, April 30th. The shares were bought at an average cost of $182.84 per share, with a total value of $249,759.44. Following the completion of the transaction, the director now directly owns 60,649 shares of the company’s stock, valued at $11,089,063.16. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Lilly Endowment Inc sold 125,284 shares of Eli Lilly and stock in a transaction dated Monday, March 8th. The stock was sold at an average price of $209.69, for a total transaction of $26,270,801.96. Following the sale, the insider now directly owns 110,422,933 shares of the company’s stock, valued at approximately $23,154,584,820.77. The disclosure for this sale can be found here. 0.09% of the stock is owned by insiders.

Eli Lilly and Profile

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

See Also: How is net asset value different from market price?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.